Scholarlink

Background <p><i>EGFR</i>-mutant lung adenocarcinoma (LUAD) exhibits significant prognostic heterogeneity despite the efficacy of tyrosine kinase inhibitors. To uncover the transcriptomic markers of rapid disease progression, we integrated clinical and transcriptomic data to develop robust prognostic biomarkers for risk stratification.</p> Methods <p>We utilized ensemble machine learning algorithms, including Random Survival Forest and XGBoost, to analyze transcriptomic data from 293 patients with <i>EGFR</i>-mutant LUAD. Single-cell transcriptomic analysis combined with copy number variation (CNV) profiling was employed to assess the cellular distribution and tumor epithelial contribution of the identified prognostic signature. The functional effects of the candidate biomarkers, <i>USP15</i> and <i>KRT17</i>, and their dynamic regulation by oncogenic EGFR signaling were experimentally validated in <i>EGFR</i>-mutant cell lines using siRNA knockdown, pharmacological blockade (osimertinib), and gain-of-function assays.</p> Results <p>The optimized XGBoost model identified a 13-gene cluster with strong predictive performance (C-index = 0.863), which was independently validated in an external cohort (log-rank <i>P</i> = 0.0117; 1-year AUC = 0.698). Single-cell transcriptomic analysis demonstrated that the detectable 11-gene subset exhibited a mixed tumor–microenvironment distribution, including expression within CNV-defined malignant epithelial cells. Functional experiments further demonstrated that <i>USP15</i> and <i>KRT17</i> promote tumor cell proliferation, clonogenic growth, and migration. Moreover, the expression of both genes was responsive to downstream EGFR signaling. Collectively, these findings establish a robust 13-gene prognostic gene cluster with a mixed cellular origin and identify <i>USP15</i>- and <i>KRT17</i>-associated biology as a promising direction for future mechanistic investigation in <i>EGFR</i>-mutant LUAD.</p> Conclusions <p>We identify a 13-gene prognostic cluster associated with poor survival in <i>EGFR</i>-mutant LUAD. These findings position the <i>EGFR</i>-regulated USP15/KRT17 axis as a novel framework for patient risk stratification, with potential implications for guiding targeted therapeutic strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A USP15/KRT17-associated 13-gene prognostic cluster and functional validation in EGFR-mutant lung adenocarcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月16日

查看全文
  • Jiamin Huang,
  • Yi Huang,
  • Qi Yuan,
  • Aiwei Tang,
  • Minzhe Su,
  • Yuanyuan Li,
  • Zhen Gan,
  • Xiuxiu Yang,
  • Junyi Song,
  • Yaokai Ye,
  • Qing Xie,
  • Liyun Huo,
  • Runmin Li,
  • Miaoling Tang,
  • Rong Lian,
  • Junchao Cai,
  • Tianyu Tao

摘要

Background

EGFR-mutant lung adenocarcinoma (LUAD) exhibits significant prognostic heterogeneity despite the efficacy of tyrosine kinase inhibitors. To uncover the transcriptomic markers of rapid disease progression, we integrated clinical and transcriptomic data to develop robust prognostic biomarkers for risk stratification.

Methods

We utilized ensemble machine learning algorithms, including Random Survival Forest and XGBoost, to analyze transcriptomic data from 293 patients with EGFR-mutant LUAD. Single-cell transcriptomic analysis combined with copy number variation (CNV) profiling was employed to assess the cellular distribution and tumor epithelial contribution of the identified prognostic signature. The functional effects of the candidate biomarkers, USP15 and KRT17, and their dynamic regulation by oncogenic EGFR signaling were experimentally validated in EGFR-mutant cell lines using siRNA knockdown, pharmacological blockade (osimertinib), and gain-of-function assays.

Results

The optimized XGBoost model identified a 13-gene cluster with strong predictive performance (C-index = 0.863), which was independently validated in an external cohort (log-rank P = 0.0117; 1-year AUC = 0.698). Single-cell transcriptomic analysis demonstrated that the detectable 11-gene subset exhibited a mixed tumor–microenvironment distribution, including expression within CNV-defined malignant epithelial cells. Functional experiments further demonstrated that USP15 and KRT17 promote tumor cell proliferation, clonogenic growth, and migration. Moreover, the expression of both genes was responsive to downstream EGFR signaling. Collectively, these findings establish a robust 13-gene prognostic gene cluster with a mixed cellular origin and identify USP15- and KRT17-associated biology as a promising direction for future mechanistic investigation in EGFR-mutant LUAD.

Conclusions

We identify a 13-gene prognostic cluster associated with poor survival in EGFR-mutant LUAD. These findings position the EGFR-regulated USP15/KRT17 axis as a novel framework for patient risk stratification, with potential implications for guiding targeted therapeutic strategies.